https://www.selleckchem.com/products/pu-h71.html
No complete responses were seen. Median overall and progression-free survival were 21.9 months [95% confidence interval (CI) 14.3-33.8] and 8.7 months (95% CI 4.8-12.3), respectively. Although most FH-RCC tumors are due to germline alterations, a significant portion result from biallelic somatic loss. Both somatic and germline FH-RCC have similar molecular characteristics, with NF2 mutations, low tumor mutational burden, and high fraction of genome altered. Although immunotherapy alone produced no objective responses, combination mTOR/VE
Like
Comment
Share
